Switch to: References

Add citations

You must login to add citations.
  1. Do Groups Have Moral Standing in Unregulated mHealth Research?Joon-Ho Yu & Eric Juengst - 2020 - Journal of Law, Medicine and Ethics 48 (S1):122-128.
    Biomedical research using data from participants’ mobile devices borrows heavily from the ethos of the “citizen science” movement, by delegating data collection and transmission to its volunteer subjects. This engagement gives volunteers the opportunity to feel like partners in the research and retain a reassuring sense of control over their participation. These virtues, in turn, give both grass-roots citizen science initiatives and institutionally sponsored mHealth studies appealing features to flag in recruiting participants from the public. But while grass-roots citizen science (...)
    Download  
     
    Export citation  
     
    Bookmark   4 citations  
  • Beyond bias and discrimination: redefining the AI ethics principle of fairness in healthcare machine-learning algorithms.Benedetta Giovanola & Simona Tiribelli - 2023 - AI and Society 38 (2):549-563.
    The increasing implementation of and reliance on machine-learning (ML) algorithms to perform tasks, deliver services and make decisions in health and healthcare have made the need for fairness in ML, and more specifically in healthcare ML algorithms (HMLA), a very important and urgent task. However, while the debate on fairness in the ethics of artificial intelligence (AI) and in HMLA has grown significantly over the last decade, the very concept of fairness as an ethical value has not yet been sufficiently (...)
    Download  
     
    Export citation  
     
    Bookmark   2 citations  
  • Communicable Disease Surveillance Ethics in the Age of Big Data and New Technology.Gwendolyn L. Gilbert, Chris Degeling & Jane Johnson - 2019 - Asian Bioethics Review 11 (2):173-187.
    Surveillance is essential for communicable disease prevention and control. Traditional notification of demographic and clinical information, about individuals with selected infectious diseases, allows appropriate public health action and is protected by public health and privacy legislation, but is slow and insensitive. Big data–based electronic surveillance, by commercial bodies and government agencies, which draws on a plethora of internet- and mobile device–based sources, has been widely accepted, if not universally welcomed. Similar anonymous digital sources also contain syndromic information, which can be (...)
    Download  
     
    Export citation  
     
    Bookmark   5 citations  
  • Community perspectives on the benefits and risks of technologically enhanced communicable disease surveillance systems: a report on four community juries.Chris Degeling, Stacy M. Carter, Antoine M. van Oijen, Jeremy McAnulty, Vitali Sintchenko, Annette Braunack-Mayer, Trent Yarwood, Jane Johnson & Gwendolyn L. Gilbert - 2020 - BMC Medical Ethics 21 (1):1-14.
    Background Outbreaks of infectious disease cause serious and costly health and social problems. Two new technologies – pathogen whole genome sequencing and Big Data analytics – promise to improve our capacity to detect and control outbreaks earlier, saving lives and resources. However, routinely using these technologies to capture more detailed and specific personal information could be perceived as intrusive and a threat to privacy. Method Four community juries were convened in two demographically different Sydney municipalities and two regional cities in (...)
    Download  
     
    Export citation  
     
    Bookmark   2 citations  
  • NHS AI Lab: why we need to be ethically mindful about AI for healthcare.Jessica Morley & Luciano Floridi - unknown
    On 8th August 2019, Secretary of State for Health and Social Care, Matt Hancock, announced the creation of a £250 million NHS AI Lab. This significant investment is justified on the belief that transforming the UK’s National Health Service (NHS) into a more informationally mature and heterogeneous organisation, reliant on data-based and algorithmically-driven interactions, will offer significant benefit to patients, clinicians, and the overall system. These opportunities are realistic and should not be wasted. However, they may be missed (one may (...)
    Download  
     
    Export citation  
     
    Bookmark